- Home
- LEGN vs GH Comparison
LEGN vs GH Comparison
Compare LEGN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- GH
- Stock Information
- Founded
- LEGN 2014
- GH 2011
- Country
- LEGN United States
- GH United States
- Employees
- LEGN N/A
- GH N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- GH Medical Specialities
- Sector
- LEGN Health Care
- GH Health Care
- Exchange
- LEGN Nasdaq
- GH Nasdaq
- Market Cap
- LEGN 7.0B
- GH 6.1B
- IPO Year
- LEGN 2020
- GH 2018
- Fundamental
- Price
- LEGN $37.19
- GH $42.63
- Analyst Decision
- LEGN Strong Buy
- GH Strong Buy
- Analyst Count
- LEGN 12
- GH 20
- Target Price
- LEGN $79.50
- GH $48.40
- AVG Volume (30 Days)
- LEGN 1.2M
- GH 2.4M
- Earning Date
- LEGN 03-11-2025
- GH 02-20-2025
- Dividend Yield
- LEGN N/A
- GH N/A
- EPS Growth
- LEGN N/A
- GH N/A
- EPS
- LEGN N/A
- GH N/A
- Revenue
- LEGN $627,241,000.00
- GH $739,016,000.00
- Revenue This Year
- LEGN $121.45
- GH $19.11
- Revenue Next Year
- LEGN $65.49
- GH $21.44
- P/E Ratio
- LEGN N/A
- GH N/A
- Revenue Growth
- LEGN 119.97
- GH 31.04
- 52 Week Low
- LEGN $30.17
- GH $15.81
- 52 Week High
- LEGN $69.24
- GH $50.89
- Technical
- Relative Strength Index (RSI)
- LEGN 54.69
- GH 50.57
- Support Level
- LEGN $33.94
- GH $34.88
- Resistance Level
- LEGN $35.77
- GH $42.97
- Average True Range (ATR)
- LEGN 1.82
- GH 3.39
- MACD
- LEGN -0.11
- GH -0.62
- Stochastic Oscillator
- LEGN 61.16
- GH 53.56
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.